Wells Fargo & Company Esperion Therapeutics, Inc. Transaction History

Wells Fargo & Company

$468 Billion
Q2 2025

A detailed history of Wells Fargo & Company transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 123,448 shares of ESPR stock, worth $220,971. This represents 0.0% of its overall portfolio holdings.

Number of Shares

123,448

Previous 1,217,541 89.86%

Holding current value

$220,971

Previous $1.75 Million 93.15%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$0.73 - $1.41 $798,687 - $1.54 Million	-1,094,093 Reduced 89.86%	123,448 $120,000
Q1 2025 May 13, 2025	BUY	$1.44 - $2.34 $1.6 Million - $2.6 Million	1,109,140 Added 1023.18%	1,217,541 $1.75 Million
Q4 2024 Feb 12, 2025	BUY	$1.61 - $3.83 $3,255 - $7,744	2,022 Added 1.9%	108,401 $238,000
Q3 2024 Nov 13, 2024	BUY	$1.61 - $2.73 $508 - $862	316 Added 0.3%	106,379 $175,000
Q2 2024 Aug 13, 2024	BUY	$1.84 - $3.24 $143,991 - $253,549	78,256 Added 281.43%	106,063 $235,000
Q1 2024 May 10, 2024	BUY	$2.02 - $3.02 $49,421 - $73,887	24,466 Added 732.3%	27,807 $74,000
Q4 2023 Feb 09, 2024	BUY	$0.73 - $3.08 $62 - $264	86 Added 2.64%	3,341 $9,000
Q3 2023 Nov 13, 2023	BUY	$0.96 - $1.79 $98 - $184	103 Added 3.27%	3,255 $3,000
Q2 2023 Aug 15, 2023	SELL	$1.2 - $1.76 $18,704 - $27,433	-15,587 Reduced 83.18%	3,152 $4,000
Q1 2023 May 12, 2023	BUY	$1.46 - $7.3 $19,701 - $98,506	13,494 Added 257.27%	18,739 $29,000
Q4 2022 Feb 13, 2023	SELL	$5.09 - $8.5 $488 - $816	-96 Reduced 1.8%	5,245 $32,000
Q3 2022 Nov 14, 2022	SELL	$5.45 - $8.13 $6,398 - $9,544	-1,174 Reduced 18.02%	5,341 $36,000
Q2 2022 Aug 12, 2022	SELL	$4.77 - $6.67 $20,692 - $28,934	-4,338 Reduced 39.97%	6,515 $41,000
Q1 2022 May 16, 2022	SELL	$3.34 - $5.56 $13,049 - $21,722	-3,907 Reduced 26.47%	10,853 $50,000
Q4 2021 Feb 14, 2022	BUY	$4.81 - $11.92 $58,340 - $144,577	12,129 Added 461.0%	14,760 $74,000
Q3 2021 Nov 15, 2021	SELL	$11.34 - $21.37 $276,231 - $520,551	-24,359 Reduced 90.25%	2,631 $31,000
Q2 2021 Aug 16, 2021	BUY	$19.4 - $28.71 $322,893 - $477,849	16,644 Added 160.87%	26,990 $572,000
Q1 2021 May 13, 2021	SELL	$25.12 - $36.89 $1.25 Million - $1.83 Million	-49,644 Reduced 82.75%	10,346 $290,000
Q4 2020 Feb 09, 2021	SELL	$24.2 - $35.76 $89,370 - $132,061	-3,693 Reduced 5.8%	59,990 $1.56 Million
Q3 2020 Nov 05, 2020	SELL	$31.18 - $52.71 $361,469 - $611,067	-11,593 Reduced 15.4%	63,683 $2.37 Million
Q2 2020 Aug 13, 2020	BUY	$30.04 - $51.31 $1.53 Million - $2.62 Million	51,076 Added 211.06%	75,276 $3.86 Million
Q1 2020 May 14, 2020	BUY	$27.44 - $73.84 $664,048 - $1.79 Million	24,200 New	24,200 $762,000

Others Institutions Holding ESPR

# of Institutions

183

Shares Held

106M

Call Options Held

139K

Put Options Held

604K

View Full List

About Esperion Therapeutics, Inc.

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $119M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

More about ESPR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Esperion Therapeutics, Inc. Transaction History